Home -> Law Blog Directory -> Patent Law Blogs -> IPBiz

Patent Law

: IPBiz

Rosetta Genomics issues press release over patent allowance

By Lawrence B. Ebert, Esq.

On 29 January 2010, Rosetta issued a press release about allowances by the USPTO of claims in two patent applications:

The first, covering human microRNA miR-21, was derived from the ?Tuschl III? patent series that is assigned to the Max Planck Society, Berlin, Germany and is used in Rosetta?s miRview? mets and miRview? squamous diagnostic assays. Rosetta holds a co-exclusive license to miR-21 in diagnostic applications, and a non-exclusive license for the research use field. The second patent application, covering Sanger viral hcmv-miR-UL112 and its precursor, was shown to suppress the human (host) immune system during viral infection. The allowed claims are directed to the miR, its hairpin, its complement, a DNA encoding the same, a sequence 80% identical to, a vector and a probe comprising the same.

Of Tuschl-I and -II, see previous IPBiz post

Max Planck GmbH goes after MIT, Whitehead, UMass

Full post as published by IPBiz on January 29, 2010 (boomark / email).